<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334747</url>
  </required_header>
  <id_info>
    <org_study_id>CKAE609A2202</org_study_id>
    <nct_id>NCT03334747</nct_id>
  </id_info>
  <brief_title>Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.</brief_title>
  <official_title>A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      KAE609 will be evaluated primarily for hepatic safety of single and multiple doses in
      sequential cohorts with increasing doses.

      This study aims to determine the maximum safe dose of the investigational drug KAE609 in
      malaria patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">May 14, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At least 2 CTCAE grades increase from baseline in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) during the 4 week study period</measure>
    <time_frame>Upto day 29 post dose</time_frame>
    <description>≥ 2 Grade (CTCAE grades) increase from baseline (at any time point during the study) in:
2 patients in a 10 patient cohort (Cohorts 1 and 2) or
3 patients in a 20 patient cohort (Cohorts 3 and 4) If above situation occurs, suspend recruitment and initiate review of liver safety (and any other relevant data) by safety review committee.Any further progression of the study is based on the decision by the safety review committee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polymerase Chain Reaction (PCR) corrected Clinical and Parasitological Cure</measure>
    <time_frame>15 and 29 days post dose</time_frame>
    <description>PCR-Corrected at Days 15 and 29 (i.e., 14 and 28 days post-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recrudescence</measure>
    <time_frame>Upto day 29 post dose</time_frame>
    <description>Time to recrudescence will be calculated from the time of first study medication to the date of first event if a patient experience the event and be censored at the time of last parasite assessment if a patient does not experience the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time</measure>
    <time_frame>Upto Day 29</time_frame>
    <description>Descriptive statistics will be presented for each treatment by Cohort. In case that a patient receives rescue medication before (parasite ) clearance, the time to event will be censored at the first use of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with parasitaemia</measure>
    <time_frame>At 12, 24 and 48 hours post dose</time_frame>
    <description>This will be determined using uncorrected parasite count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Peak Observed Concentration (Cmax)</measure>
    <time_frame>Upto day 15 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>Upto day 15 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time after administration of a drug when the maximum plasma concentrations is reached (Tmax)</measure>
    <time_frame>Upto day 15 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T½)</measure>
    <time_frame>Upto day 15 post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Adequate Clinical and Parasitological Response</measure>
    <time_frame>15 and 29 days post dose</time_frame>
    <description>PCR-Uncorrected adequate clinical and parasitological response (ACPR) at Days 15 and 29 (i.e., 14 and 28 days post-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance Time</measure>
    <time_frame>Upto Day 29</time_frame>
    <description>Descriptive statistics will be presented for each treatment by Cohort. In case that a patient receives rescue medication before (fever) clearance, the time to event will be censored at the first use of rescue medication.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Treatment arm 1: KAE609 10 mg Single Dose (SD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COHORT 1_Treatment arm 1: KAE609 10 mg once daily (QD) for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 2:Coartem Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COHORT 1_Treatment arm 2: Coartem® twice a day (BID) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 3:KAE609 25 mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COHORT 2_Treatment arm 3: KAE609 25 mg once daily (QD) for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 4:KAE609 10 mg 3 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COHORT 2_Treatment arm 4: KAE609 10 mg (QD) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 5:Coartem Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COHORT 2_Treatment arm 5: Coartem® twice a day (BID) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 6:KAE609 50 mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COHORT 3_Treatment Arm 6: KAE609 50 mg once daily (QD) for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 7:KAE609 25 mg 3 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COHORT 3_Treatment Arm 7: KAE609 25 mg once daily (QD) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 8:Coartem Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COHORT 3_Treatment arm 8: Coartem® twice a day (BID) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 9:KAE609 75 mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COHORT 4_Treatment Arm 9: KAE609 75 mg once daily (QD) for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 10:KAE609 50 mg 3 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COHORT 4_Treatment Arm 10: KAE609 50 mg once daily (QD) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 11:Coartem Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COHORT 4_Treatment Arm 11: Coartem® twice a day (BID) for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAE609</intervention_name>
    <description>Exploration of different doses of KAE609 to establish safety profile.</description>
    <arm_group_label>Treatment arm 1: KAE609 10 mg Single Dose (SD)</arm_group_label>
    <arm_group_label>Treatment arm 3:KAE609 25 mg SD</arm_group_label>
    <arm_group_label>Treatment arm 4:KAE609 10 mg 3 Days</arm_group_label>
    <arm_group_label>Treatment arm 6:KAE609 50 mg SD</arm_group_label>
    <arm_group_label>Treatment arm 7:KAE609 25 mg 3 Days</arm_group_label>
    <arm_group_label>Treatment arm 9:KAE609 75 mg SD</arm_group_label>
    <arm_group_label>Treatment arm 10:KAE609 50 mg 3 Days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coartem</intervention_name>
    <description>Control Arm</description>
    <arm_group_label>Treatment arm 2:Coartem Control</arm_group_label>
    <arm_group_label>Treatment arm 5:Coartem Control</arm_group_label>
    <arm_group_label>Treatment arm 8:Coartem Control</arm_group_label>
    <arm_group_label>Treatment arm 11:Coartem Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        KEY Inclusion Criteria:

          1. Male and female patients ≥ 18 years with a body weight ≥ 45 kg.

          2. Microscopic confirmation of acute uncomplicated P. falciparum using by Giemsa-stained
             thick film.

          3. P. falciparum parasitaemia of 500 to 50 000 parasites/µL.

          4. Axillary temperature ≥ 37.5ºC or oral/tympanic/rectal temperature ≥ 38.0ºC; or history
             of fever during the previous 24 hours.

          5. Written informed consent must be obtained before any study assessment is performed. If
             the patient is unable to write, then a witnessed consent according to local ethical
             standards is permitted.

        KEY Exclusion Criteria:

          1. Mixed Plasmodium infections.

          2. Signs and symptoms of severe malaria according to World Health Organization (WHO) 2016
             criteria (WHO 2016).

          3. Known liver abnormalities, liver cirrhosis (compensated or decompensated), known
             active or history of hepatitis B or C (testing not required), known gallbladder or
             bile duct disease, acute or chronic pancreatitis.

          4. Clinical or laboratory evidence of any of the following:

          5. AST/ALT &gt; 1.5 x the upper limit of normal range (ULN), regardless of the level of
             total bilirubin

          6. AST/ALT &gt; 1.0 and ≤ 1.5 x ULN and total bilirubin is &gt; ULN

          7. Total bilirubin &gt; 2 x ULN, regardless of the level of AST/ALT

          8. History of photodermatitis/increased sensitivity to sun.

          9. Pregnant or nursing (lactating) women.

         10. Known disturbances of electrolyte balance, e.g. hypokalemia, hypocalcemia or
             hypomagnesemia.

         11. Moderate to severe anemia (Hemoglobin level &lt;8 g/dL).

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kintampo</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Navrango</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sotuba</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Ghana</country>
    <country>Mali</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uncomplicated Plasmodium falciparum Malaria.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

